3
ALL1
ANI Pharmaceuticals Inc1
Locus Biosciences1
Somerset Pharmaceuticals IncYear
3
ALL2
20221
2020DEALS // DEV.
3
ALL1
Deals2
DevelopmentsCountry
3
ALL3
U.S.A3
ALL2
Inapplicable1
PremierTherapeutic Area
3
ALL3
Infections and Infectious DiseasesStudy Phase
3
ALL1
Approved FDF1
Phase II1
UndisclosedDeal Type
3
ALL2
Inapplicable1
PartnershipProduct Type
3
ALL1
Antibiotic1
Microorganism1
Other Small MoleculeDosage Form
3
ALL1
Intraurethral Infusion1
Oral Tablet1
UndisclosedLead Product
3
ALL1
LBP-EC011
Sulfamethoxazole1
TrimethoprimTarget
3
ALL1
Dihydropteroate synthase1
Tetrahydrofolate dehydrogenase1
UndisclosedLead Product(s) : Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
Details : Trimethoprim is an antibiotic used to treat bacterial infections. It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections.
Product Name : Trimethoprim-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 16, 2022
Lead Product(s) : Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBP-EC01,Sulfamethoxazole,Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LBP-EC01 is a Locus crPhage® therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting th...
Product Name : LBP-EC01
Product Type : Microorganism
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : LBP-EC01,Sulfamethoxazole,Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfamethoxazole,Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Premier
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under terms of this partnership, Somerset Pharma will supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19, to Premier.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 08, 2020
Lead Product(s) : Sulfamethoxazole,Trimethoprim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Premier
Deal Size : Undisclosed
Deal Type : Partnership